On the public citation graph

Networking for new drugs

0 signed · 60 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1038/nature06757openalex-snapshot
Variations in DNA elucidate molecular networks that cause disease
inferredcites →https://doi.org/10.1038/nature06758openalex-snapshot
Genetics of gene expression and its effect on disease
inferredcites →https://doi.org/10.1038/nrd3375openalex-snapshot
Phase III and submission failures: 2007–2010
inferredcites →https://doi.org/10.1128/jb.181.13.3981-3993.1999openalex-snapshot
Escherichia coli Mutants Lacking All Possible Combinations of Eight Penicillin Binding Proteins: Viability, Characteristics, and Implications for Peptidoglycan Synthesis
inferredcites →https://doi.org/10.1371/journal.pcbi.1000976openalex-snapshot
The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications
inferredcites →https://doi.org/10.1371/journal.pcbi.1002037openalex-snapshot
Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1002/9781118778166.ch25openalex-snapshot
From Catalysis to Mass Action: The Evolution of CHDI Foundation, a Drug‐Development Organization Devoted to Huntington's Disease
inferred← citeshttps://doi.org/10.1002/9781394182862.ch1openalex-snapshot
Introduction
inferred← citeshttps://doi.org/10.1002/9783527684403.ch16openalex-snapshot
From Marine Organism to Potential Drug: Using Innovative Techniques to Identify and Characterize Novel Compounds − a Bottom‐Up Approach
inferred← citeshttps://doi.org/10.1002/ana.24804openalex-snapshot
Isoflurane prevents acquired epilepsy in rat models of temporal lobe epilepsy
inferred← citeshttps://doi.org/10.1002/iub.1040openalex-snapshot
From protein interaction networks to novel therapeutic strategies
inferred← citeshttps://doi.org/10.1002/minf.202200190openalex-snapshot
Advances in Computational Polypharmacology
inferred← citeshttps://doi.org/10.1002/pca.3477openalex-snapshot
Integrating Metabolomic Analysis, Network Pharmacology, and Molecular Docking to Underlying Pharmacological Mechanism and Ethnobotanical Rationalization for Diabetes Mellitus: Study on Medicinal Plant Fibraurea tinctoria Lour.
inferred← citeshttps://doi.org/10.1007/978-3-319-06419-2_38openalex-snapshot
Motility Contrast Imaging and Tissue Dynamics Spectroscopy
inferred← citeshttps://doi.org/10.1007/978-94-017-8914-1_23openalex-snapshot
What New Modeling Approaches Will Help Us Identify Promising Drug Treatments?
inferred← citeshttps://doi.org/10.1007/978-981-13-0944-1_13openalex-snapshot
Parkinson Disease Therapies and Drugs
inferred← citeshttps://doi.org/10.1007/s13311-013-0250-1openalex-snapshot
Searching for the Ideal Antiepileptogenic Agent in Experimental Models: Single Treatment Versus Combinatorial Treatment Strategies
inferred← citeshttps://doi.org/10.1016/b978-0-08-102083-8.00001-7openalex-snapshot
Multitargeting Heterocycles
inferred← citeshttps://doi.org/10.1016/bs.apha.2019.07.001openalex-snapshot
Modern traditional Chinese medicine: Identifying, defining and usage of TCM components
inferred← citeshttps://doi.org/10.1016/j.ailsci.2024.100094openalex-snapshot
Origins and progression of the polypharmacology concept in drug discovery
inferred← citeshttps://doi.org/10.1016/j.drudis.2017.03.001openalex-snapshot
Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins
inferred← citeshttps://doi.org/10.1016/j.ejmcr.2025.100291openalex-snapshot
Dual-target candidate compounds from a transformer chemical language model contain characteristic structural features
inferred← citeshttps://doi.org/10.1016/j.eplepsyres.2015.11.003openalex-snapshot
Network pharmacology for antiepileptogenesis: Tolerability of multitargeted drug combinations in nonepileptic vs. post-status epilepticus mice
inferred← citeshttps://doi.org/10.1016/j.eplepsyres.2019.02.010openalex-snapshot
Network pharmacology for antiepileptogenesis: Tolerability and neuroprotective effects of novel multitargeted combination treatments in nonepileptic vs. post-status epilepticus mice
inferred← citeshttps://doi.org/10.1016/j.expneurol.2024.114962openalex-snapshot
A comparison of the antiepileptogenic efficacy of two rationally chosen multitargeted drug combinations in a rat model of posttraumatic epilepsy
inferred← citeshttps://doi.org/10.1016/j.jep.2012.01.035openalex-snapshot
Omics and its potential impact on R&D and regulation of complex herbal products
inferred← citeshttps://doi.org/10.1016/j.jep.2012.02.028openalex-snapshot
Traditional Chinese medicine research in the post-genomic era: Good practice, priorities, challenges and opportunities
inferred← citeshttps://doi.org/10.1016/j.nbd.2019.104664openalex-snapshot
Proof-of-concept that network pharmacology is effective to modify development of acquired temporal lobe epilepsy
inferred← citeshttps://doi.org/10.1016/j.nbd.2020.105227openalex-snapshot
Systematic evaluation of rationally chosen multitargeted drug combinations: a combination of low doses of levetiracetam, atorvastatin and ceftriaxone exerts antiepileptogenic effects in a mouse model of acquired epilepsy
inferred← citeshttps://doi.org/10.1016/j.neuropharm.2019.04.011openalex-snapshot
The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2021.107934openalex-snapshot
New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal?
inferred← citeshttps://doi.org/10.1016/j.phrs.2016.06.018openalex-snapshot
Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature
inferred← citeshttps://doi.org/10.1016/j.rechem.2024.101376openalex-snapshot
Systematic identification and characterization of compounds with reliable activity against multiple target proteins from different classes
inferred← citeshttps://doi.org/10.1016/j.xcrp.2024.102255openalex-snapshot
Generation of dual-target compounds using a transformer chemical language model
inferred← citeshttps://doi.org/10.1016/j.xcrp.2025.103054openalex-snapshot
Chemical language models for generating compounds with triple-target activity
inferred← citeshttps://doi.org/10.1021/ja504810zopenalex-snapshot
Systems Biology Brings New Dimensions for Structure-Based Drug Design
inferred← citeshttps://doi.org/10.1021/jm400856topenalex-snapshot
Polypharmacology – Foe or Friend?
inferred← citeshttps://doi.org/10.1038/ismej.2012.141openalex-snapshot
The chemical interactome space between the human host and the genetically defined gut metabotypes
inferred← citeshttps://doi.org/10.1038/nrd3681openalex-snapshot
Diagnosing the decline in pharmaceutical R&D efficiency
inferred← citeshttps://doi.org/10.1038/nrd4126openalex-snapshot
New avenues for anti-epileptic drug discovery and development
inferred← citeshttps://doi.org/10.1038/psp.2014.1openalex-snapshot
VNP: Interactive Visual Network Pharmacology of Diseases, Targets, and Drugs
inferred← citeshttps://doi.org/10.1038/srep07608openalex-snapshot
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy
inferred← citeshttps://doi.org/10.1039/c6md00129gopenalex-snapshot
The evolution of drug discovery: from phenotypes to targets, and back
inferred← citeshttps://doi.org/10.1080/07391102.2022.2135597openalex-snapshot
Drug candidates and potential targets ofCurculigospp. compounds for treating diabetes mellitus based on network pharmacology, molecular docking and molecular dynamics simulation
inferred← citeshttps://doi.org/10.1111/cas.12183openalex-snapshot
Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming
inferred← citeshttps://doi.org/10.1111/epi.16450openalex-snapshot
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
inferred← citeshttps://doi.org/10.1142/9789814749411_0001openalex-snapshot
DISCOVERY OF MOLECULARLY TARGETED THERAPIES
inferred← citeshttps://doi.org/10.1177/0269881114553252openalex-snapshot
Antidepressant drug development: Focus on triple monoamine reuptake inhibition
inferred← citeshttps://doi.org/10.1177/1087057112454741openalex-snapshot
Novel Stem Cell–Based Drug Discovery Platforms for Cardiovascular Disease
inferred← citeshttps://doi.org/10.1186/s13023-014-0199-0openalex-snapshot
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
inferred← citeshttps://doi.org/10.12688/f1000research.3751.1openalex-snapshot
Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy
inferred← citeshttps://doi.org/10.12688/f1000research.3751.2openalex-snapshot
Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy
inferred← citeshttps://doi.org/10.12688/f1000research.4019openalex-snapshot
Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy
inferred← citeshttps://doi.org/10.12688/f1000research.4270openalex-snapshot
Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy
inferred← citeshttps://doi.org/10.12688/f1000research.5564.1openalex-snapshot
Collaboration for rare disease drug discovery research
inferred← citeshttps://doi.org/10.18214/jkaem.2012.14.2.55openalex-snapshot
Strategies for Diagnosis and Treatment of Charcot-Marie-Tooth Disease
inferred← citeshttps://doi.org/10.2174/1381612822666160418121534openalex-snapshot
Systems Pharmacology: A Unified Framework for Prediction of Drug-Target Interactions
inferred← citeshttps://doi.org/10.3389/fphar.2021.730257openalex-snapshot
Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy
inferred← citeshttps://doi.org/10.3389/fpsyt.2020.562660openalex-snapshot
Challenges of Psychiatry Drug Development and the Role of Human Pharmacology Models in Early Development—A Drug Developer's Perspective
inferred← citeshttps://doi.org/10.4155/fmc.14.25openalex-snapshot
Polypharmacology: The Rise of Multitarget Drugs over Combination Therapies
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.